Join Growin Stock Community!

保瑞6472.TW Overview

TW StockBiotech. & Medical
(No presentation for 6472)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

保瑞(6472)Overall Performance

保瑞(6472)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

保瑞(6472) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

保瑞(6472)Key Information

保瑞(6472)Profile

Bora Pharmaceuticals Co., LTD. researches and develops, manufactures, distributes, and sells pharmaceuticals worldwide. The company operates through Sales, Contract Development & Manufacturing Organization, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services, including clinical and commercial manufacturing, pharmaceutical development, packaging and serialization, analytical and microbiology testing, and regulatory affairs services. In addition, it provides food and vitamin supplements, and skincare products; and biotechnical services. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.

保瑞(6472)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
26.15
PE Ratio (TTM)
18.55
Forward PE
18.26
PS Ratio (TTM)
3.03
PB Ratio
3.85
Price-to-FCF
6.07
METRIC
VALUE
vs. INDUSTRY
Gross Margin
39.99%
Net Margin
16.35%
Revenue Growth (YoY)
34.88%
Profit Growth (YoY)
10.18%
3-Year Revenue Growth
52.52%
3-Year Profit Growth
60.21%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
26.15
PE Ratio (TTM)
18.55
Forward PE
18.26
PS Ratio (TTM)
3.03
PB Ratio
3.85
Price-to-FCF
6.07
Gross Margin
39.99%
Net Margin
16.35%
Revenue Growth (YoY)
34.88%
Profit Growth (YoY)
10.18%
3-Year Revenue Growth
52.52%
3-Year Profit Growth
60.21%
default symbol

6472

保瑞

485.00D

-1.86%

(-0.02)

  • When is 6472's latest earnings report released?

    The most recent financial report for 保瑞 (6472) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6472's short-term business performance and financial health. For the latest updates on 6472's earnings releases, visit this page regularly.

  • Where does 6472 fall in the P/E River chart?

    According to historical valuation range analysis, 保瑞 (6472)'s current price-to-earnings (P/E) ratio is 37.94, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 6472?

    According to the latest financial report, 保瑞 (6472) reported an Operating Profit of 1.06B with an Operating Margin of 22.12% this period, representing a decline of 12.66% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6472's revenue growth?

    In the latest financial report, 保瑞 (6472) announced revenue of 4.81B, with a Year-Over-Year growth rate of -14.4%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6472 have?

    At the end of the period, 保瑞 (6472) held Total Cash and Cash Equivalents of 4.41B, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6472 go with three margins increasing?

    In the latest report, 保瑞 (6472) achieved the “three margins increasing” benchmark, with a gross margin of 45.19%%, operating margin of 22.12%%, and net margin of 13.25%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6472's profit trajectory and future growth potential.

  • Is 6472's EPS continuing to grow?

    According to the past four quarterly reports, 保瑞 (6472)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 5.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6472?

    保瑞 (6472)'s Free Cash Flow (FCF) for the period is 1.79B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 134.76% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.